Chee Wai Chua

Chee Wai Chua

Auto-generated profile, based on publicly available information

Chee Wai Chua

Cancer Biology Group, Department of Anatomy and Departments of 2 Pathology and 3 Surgery, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2005 in Cancer Research
Verified
Journal Article
Closed access
PDF file
WKWai Kei Kwok
Wai Kei Kwok
MLMing-Tat Ling
Ming-Tat Ling
TLTak-Wing Lee
Tak-Wing Lee
TLTracy C.M. Lau
Tracy C.M. Lau
CZChun Zhou
Chun Zhou
XWXianghong Wang
Xianghong Wang
Androgen-independent metastatic prostate cancer is the main obstacle in the treatment of this cancer. Unlike a majority of solid cancers, prostate cancer usually shows poor response to chemotherapeutic drugs. In this study, we have shown a potential novel target, TWIST, a highly conserved bHLH transcription factor, in the treatment of prostate cancer. Using malignant and nonmalignant prostate tissues, we found that TWIST expression was highly expressed in the majority (90%) of prostate cancer tissues but only in a small percentage (6.7%) of benign prostate hyperplasia. In addition, the TWIST expression levels were positively correlated with Gleason grading and metastasis, indicating its role in the development and progression of prostate cancer. Furthermore, down-regulation of TWIST through small interfering RNA in androgen-independent prostate cancer cell lines, DU145 and PC3, resulted in increased sensitivity to the anticancer drug taxol-induced cell death which was associated with decreased Bcl/Bax ratio, leading to activation of the apoptosis pathway. More importantly, inactivation of TWIST suppressed migration and invasion abilities of androgen-independent prostate cancer cells, which was correlated with induction of E-cadherin expression as well as morphologic and molecular changes associated with mesenchymal to epithelial transition. These results were further confirmed on the androgen-dependent LNCaP cells ectopically expressing the TWIST protein. Our results have identified TWIST as a critical regulator of prostate cancer cell growth and suggest a potential therapeutic approach to inhibit the growth and metastasis of androgen-independent prostate cancer through inactivation of the TWIST gene.

21 September 2014 in Nature Cell Biology
Verified
Journal Article
Open access
PDF file
CCChee Wai Chua
Chee Wai Chua
MSMaho Shibata
Maho Shibata
MLMing Lei
Ming Lei
RTRoxanne Toivanen
Roxanne Toivanen
LBLaMont J. Barlow
LaMont J. Barlow
MSMichael M. Shen
Michael M. Shen
The intrinsic ability to exhibit self-organizing morphogenetic properties in ex vivo culture may represent a general property of tissue stem cells. Here we show that single luminal stem/progenitor cells can generate prostate organoids in a three-dimensional culture system in the absence of stroma. Organoids generated from CARNs (castration-resistant Nkx3.1-expressing cells) or normal prostate epithelia exhibit tissue architecture containing luminal and basal cells, undergo long-term expansion in culture and exhibit functional androgen receptor signalling. Lineage-tracing demonstrates that luminal cells are favoured for organoid formation and generate basal cells in culture. Furthermore, tumour organoids can initiate from CARNs after oncogenic transformation and from mouse models of prostate cancer, and can facilitate analyses of drug response. Finally, we provide evidence supporting the feasibility of organoid studies of human prostate tissue. Our studies underscore the progenitor properties of luminal cells, and identify in vitro approaches for studying prostate biology.

16 December 2020 in Communications Biology
Verified
Journal Article
Open access
PDF file
BDBaijun Dong
Baijun Dong
JMJuju Miao
Juju Miao
YWYanqing Wang
Yanqing Wang
WLWenqin Luo
Wenqin Luo
ZJZhongzhong Ji
Zhongzhong Ji
Wei-Qiang GaoWei-Qiang Gao
Wei-Qiang Gao
Neuroendocrine prostate cancer is one of the most aggressive subtypes of prostate tumor. Although much progress has been made in understanding the development of neuroendocrine prostate cancer, the cellular architecture associated with neuroendocrine differentiation in human prostate cancer remain incompletely understood. Here, we use single-cell RNA sequencing to profile the transcriptomes of 21,292 cells from needle biopsies of 6 castration-resistant prostate cancers. Our analyses reveal that all neuroendocrine tumor cells display a luminal-like epithelial phenotype. In particular, lineage trajectory analysis suggests that focal neuroendocrine differentiation exclusively originate from luminal-like malignant cells rather than basal compartment. Further tissue microarray analysis validates the generality of the luminal phenotype of neuroendocrine cells. Moreover, we uncover neuroendocrine differentiation-associated gene signatures that may help us to further explore other intrinsic molecular mechanisms deriving neuroendocrine prostate cancer. In summary, our single-cell study provides direct evidence into the cellular states underlying neuroendocrine transdifferentiation in human prostate cancer.

26 March 2007 in Histopathology
Verified
Journal Article
Closed access
PDF file
HYH‐F Yuen
H‐F Yuen
CCC‐W Chua
C‐W Chua
YCY‐P Chan
Y‐P Chan
YWY‐C Wong
Y‐C Wong
XWX Wang
X Wang
KCK‐W Chan
K‐W Chan

1 April 2007 in Human Pathology
Verified
Journal Article
Closed access
ZZZheng Zhang
Zheng Zhang
DXDan Xie
Dan Xie
XLXin Li
Xin Li
YWYogn-Chuan Wong
Yogn-Chuan Wong
DXDianqi Xin
Dianqi Xin
XWXianghong Wang
Xianghong Wang

28 June 2005 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
CCChee‐Wai Chua
Chee‐Wai Chua
DLDavy Tak‐Wing Lee
Davy Tak‐Wing Lee
MLMing‐Tat Ling
Ming‐Tat Ling
CZChun Zhou
Chun Zhou
KMKwan Man
Kwan Man
YWYong‐Chuan Wong
Yong‐Chuan Wong
FTY720, a derivative of fungus, has demonstrated dramatic anticancer effect in several malignancies recently. Our study evaluates the therapeutic potential of FTY720 in the treatment of androgen‐independent prostate cancer using a human prostate cancer xenograft in nude mice. CWR22R, an androgen‐independent human prostate tumor xenograft was inoculated into castrated nude mice and the animals were administrated with either normal saline or FTY720 (10 mg/kg) through intraperitoneal (i.p.) injection for 20 days. Body weight and tumor volume were recorded every 2 days, and serum prostate specific antigen (PSA) levels were also measured before and after the treatment. The effect of FTY720 on tumor cell proliferation was examined using antibodies against PCNA and Ki‐67 by immunohistochemical staining, MTT assay and colony forming assay, whereas apoptotic effect of FTY720 was evaluated by TUNEL assay and immunostaining using antibodies against cleaved caspase 3 and Bcl‐2. In addition, the potential inhibitory effect of FTY720 on prostate cancer angiogenesis and metastasis was investigated by immunostaining of CD31, VEGF, E‐cadherin and β‐catenin. Our results showed that FTY720 treatment led to suppression of CWR22R tumor growth without causing any detectable side effects in nude mice. The FTY720‐induced tumor suppression was correlated with decreased serum PSA level as well as reduced proliferation rate, suppression of angiogenic factors, and restoration of E‐cadherin and β‐catenin expression. In addition, the FTY720‐treated tumors showed increased apoptosis rate demonstrated by increased TUNEL‐ and cleaved caspase 3‐positive cells, and decreased Bcl‐2 expression. Our results suggest a potential novel agent in the suppression of androgen‐independent prostate cancer.